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The clinical spectrum of the congenital
myasthenic syndrome resulting from COL13A1
mutations
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Vahidi Mehrjardi,8 Gabriel Chow,9 Aisling Carr,10 Adnan Manzur,11 Stephanie Robb,11
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Next generation sequencing techniques were recently used to show mutations in COL13A1 cause synaptic basal lamina-associated
congenital myasthenic syndrome type 19. Animal studies showed COL13A1, a synaptic extracellular-matrix protein, is involved in
the formation and maintenance of the neuromuscular synapse that appears independent of the Agrin-LRP4-MuSK-DOK7 acetyl-
choline receptor clustering pathway. Here, we report the phenotypic spectrum of 16 patients from 11 kinships harbouring homo-
zygous or heteroallelic mutations in COL13A1. Clinical presentation was mostly at birth with hypotonia and breathing and feeding
difﬁculties often requiring ventilation and artiﬁcial feeding. Respiratory crisis related to recurrent apnoeas, sometimes triggered by
chest infections, were common early in life but resolved over time. The predominant pattern of muscle weakness included bilateral
ptosis (non-fatigable in adulthood), myopathic facies and marked axial weakness, especially of neck ﬂexion, while limb muscles
were less involved. Other features included facial dysmorphism, skeletal abnormalities and mild learning difﬁculties. All patients
tested had results consistent with abnormal neuromuscular transmission. Muscle biopsies were within normal limits or showed
non-speciﬁc changes. Muscle MRI and serum creatine kinase levels were normal. In keeping with COL13A1 mutations affecting
both synaptic structure and presynaptic function, treatment with 3,4-diaminopyridine and salbutamol resulted in motor and
respiratory function improvement. In non-treated cases, disease severity and muscle strength improved gradually over time and
several adults recovered normal muscle strength in the limbs. In summary, patients with COL13A1 mutations present mostly with
severe early-onset myasthenic syndrome with feeding and breathing difﬁculties. Axial weakness is greater than limb weakness.
Disease course improves gradually over time, which could be consistent with the less prominent role of COL13A1 once the
neuromuscular junction is mature. This report emphasizes the role of collagens at the human muscle endplate and should facilitate
the recognition of this disorder, which can beneﬁt from pharmacological treatment.
1 Neurosciences Group, Nufﬁeld Department of Clinical Neurosciences, Weatherall Institute of Molecular Medicine, University of
Oxford, Oxford OX3 9DS, UK
2 Nufﬁeld Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK
3 Departamento de Neurologia, Faculdade de Medicina da Universidade de Sa˜o Paulo (FMUSP), Sa˜o Paulo, Brazil
4 Neuromuscular disorders Group, Child Neurology Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute
(VHIR), Barcelona, Spain
5 University of British Columbia, Vancouver, British Columbia, Canada
doi:10.1093/brain/awz107 BRAIN 2019: 142; 1547–1560 | 1547
Received December 17, 2018. Revised February 8, 2019. Accepted February 22, 2019. Advance Access publication May 13, 2019
 The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/6/1547/5488581 by St G
eorge's U
niversity of London user on 02 O
ctober 2019
6 Department of Neurology, H. Houston Merritt Neuromuscular Research Center, Columbia University Medical Center, New
York, NY, USA
7 Molecular and Clinical Sciences Institute, St. George’s, University of London, Cranmer Terrace, London SW17 0RE, UK
8 Medical Genetics Research Centre, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
9 Department of Paediatric Neurology, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Hucknall Road,
Nottingham NG5 1PB, UK
10 MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK
11 Dubowitz Neuromuscular Centre and MRC Centre for Neuromuscular Diseases, UCL Great Ormond Street Institute of Child
Health, London WC1N 3JH, UK
12 Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester University NHS Foundation Trust, Health
Innovation Manchester, Manchester M13 9WL, UK
13 Department of Paediatric Neurology, Royal Preston Hospital, Preston PR2 9HT, UK
14 Department of Clinical Neurophysiology, Hospital Universitari Vall d’Hebron, Barcelona Spain
15 Friedrich-Baur-Institute at the Department of Neurology, University Hospital LMU Munich, Munich, Germany
16 Institute of Genetic Medicine, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK
17 Department of Neuropathology, John Radcliffe Hospital NHS Foundation Trust, Oxford OX3 9DU, UK
18 Department of Clinical Neurophysiology, John Radcliffe Hospital NHS Foundation Trust, Oxford OX3 9DU, UK
19 Department of Paediatric Neurology, John Radcliffe Hospital NHS Foundation Trust, Oxford OX3 9DU, UK
20 Department of Neuropediatrics and Muscle Disorders, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg,
Germany
21 Centro Nacional de Ana´lisis Geno´mico (CNAG-CRG), Center for Genomic Regulation, Barcelona Institute of Science and
Technology (BIST), Barcelona, Spain
22 Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada
23 Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, Canada
Correspondence to: Dr Pedro M. Rodrı´guez Cruz
Nufﬁeld Department of Clinical Neurosciences, Neurosciences Group, Weatherall Institute of Molecular Medicine
John Radcliffe Hospital, Oxford OX3 9DS, UK
E-mail: pedro.rodriguezcruz@ndcn.ox.ac.uk
Correspondence may also be addressed to: Prof David Beeson
Nufﬁeld Department of Clinical Neurosciences, Neurosciences Group, Weatherall Institute of Molecular Medicine
John Radcliffe Hospital, Oxford OX3 9DS, UK
E-mail: david.beeson@ndcn.ox.ac.uk
Keywords: congenital myasthenic syndromes; COL13A1; synaptic basal lamina; salbutamol; 3,4-diaminopyridine
Abbreviations: 3,4-DAP = 3,4-diaminopyridine; CMS = congenital myasthenic syndromes
Introduction
The use of next generation sequencing (NGS) in clinical
diagnosis is allowing the identiﬁcation of novel disease
genes in neuromuscular disorders (Taylor et al., 2015).
This technology has been crucial to expand the genetic
spectrum of the congenital myasthenic syndromes (CMS),
which currently exceeds 30 genes (Rodrı´guez Cruz et al.,
2018). Causative genes encode for proteins that are essen-
tial for the integrity of neuromuscular transmission. The
most common classiﬁcation of CMS relies on the location
of the encoded protein into presynaptic, synaptic or basal
lamina-associated and postsynaptic syndromes. All sub-
types of CMS share the feature of fatigable muscle weak-
ness but age of onset, presenting symptoms, distribution of
weakness, and response to treatment vary depending on the
molecular mechanism that results from the underlying gen-
etic defect.
Mutations in COL13A1 were recently identiﬁed as the
cause of autosomal recessive synaptic basal lamina-asso-
ciated CMS type 19 (Logan et al., 2015). COL13A1
encodes the collagen type XIII alpha1 chain (COL13A1),
which is a single-pass type II transmembrane protein made
of a short intracellular domain, a single transmembrane
domain, and a triple-helical collagenous ectodomain
(Fig. 1A) (Pihlajaniemi and Tamminen, 1990). Unlike most
of the collagens, COL13A1 is anchored to the plasma mem-
brane by a hydrophobic transmembrane segment (Ha¨gg
et al., 1998). The presence of a proprotease recognition
site in the ectodomain allows the C-terminus to be proteo-
lytically cleaved into a soluble form that is part of the basal
lamina. Of note, COL13A1 transcripts undergo complex
alternative splicing (Pihlajaniemi and Tamminen, 1990).
The overall function of the COL13A1 gene product
is not well known, although mRNA expression has
been detected at low levels in a wide range of tissues
[EMBL-EBI Expression Atlas, https://www.ebi.ac.uk/gxa/
home (Petryszak et al., 2016)], suggesting a general role
in the function of connective tissues such as cell-matrix
and cell-cell interactions (Nykvist et al., 2000; Tu et al.,
2002). This is also the case for muscle tissue although it
should be noted that these studies did not take into account
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Figure 1 Schematic representation of full-length COL13A1, location of genetic variants and pedigrees of families reported.
(A) COL13A1_001 (NP_001123575) consist of a short intracellular domain (NC1), a single transmembrane domain (TM), and the extracellular
region with three collagenous domains (COL1–3) separated by short non-collagenous domains (NC2–3). The proprotease recognition site is
labelled in red. Numbers indicate the amino acid residues composing each domain and the location of the pathogenic variants identified. Because
COL13A1 undergoes complex alternative splicing, primary structures can vary. (B) Pedigrees of families included in this report. *An elder sibling
from Patient 5 with similar symptoms died at an early age but genetic confirmation was not available. **Patient 15 was initially diagnosed with
congenital insensitivity to pain with anhidrosis at the age of 1 year due to a homozygous NTRK1 mutation (Mardy et al., 1999). Patient 16,
heterozygous for the NTRK1 variant, was diagnosed with a myasthenic syndrome. This prompted the re-evaluation of the proband in whom a
myasthenic pattern of muscle activation was found on neurophysiological studies (Raspall-Chaure et al., 2005). Circles = female; squares = male;
filled symbols = affected; open symbols = unaffected; strikethrough = deceased. (C) Protein alignments were performed using the Clustal Omega
multiple sequence alignment program (https://www.ebi.ac.uk/Tools/msa/clustalo/).
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expression from sub-synaptic nuclei that are key in deter-
mining protein expression levels at the neuromuscular junc-
tion (Schaeffer et al., 2001).
Studies using transgenic mice have shown that muscle-
derived COL13A1 is essential for the maturation of the
neuromuscular junction at both pre- and postsynaptic levels
(Latvanlehto et al., 2010; Ha¨ro¨nen et al., 2017). Col13a1/
animals showed considerable presynaptic defects such as ab-
normal clustering of synaptic vesicles at the nerve terminal,
reduced terminal complexity with defective nerve endings and
terminal Schwann cells that were unable to cover the muscle
endplates. The postsynaptic structures showed abnormal mat-
uration with endplates that remained small, immature and
fragmented compared to wild-type animals. In keeping with
this, experimental studies on C2C12 muscle cell cultures have
shown abnormal agrin-induced clustering of acetylcholine re-
ceptors (AChRs) with COL13A1 loss of function (Logan
et al., 2015). Interestingly, the deleterious effect on AChR
clustering appears to be independent of any dramatic effect
in vivo on key AChR-clustering-pathway proteins MuSK
and DOK7 (Logan et al., 2015). More recent studies in
Col13a1/ animals have shown that the disease tends to
stabilize in adulthood once the neuromuscular junction is
mature, suggesting that this is collagen is particularly relevant
during development and early life (Zainul et al., 2018).
Here we review in detail the mutational and clinical spec-
trum of disease associated with COL13A1-CMS in order to
produce a detailed clinical picture that allows increased
recognition of this disorder.
Materials and methods
Next-generation and conventional Sanger sequencing were used
to identify the underlying genetic mutations in COL13A1 in 16
subjects from 11 different kinships. They all shared similar clin-
ical features and had abnormalities in neurophysiological testing
suggestive of abnormal neuromuscular transmission. The gen-
etics of Cases 1–3 were previously reported by Logan et al.
(2015) together with a short clinical description.
Identification of COL13A1-CMS
cases
A total of 16 patients (eight females) from 11 different kin-
ships were included (Fig. 1B). Consanguinity was reported in
seven families. Details on ethnicity are provided in Table 1.
Genetic analysis
Genomic DNA was isolated from patients’ and parents’ blood
by standard methods. Exome sequencing was carried out using
the manufacturer’s speciﬁcations. Sanger sequencing was per-
formed with primers covering exonic and ﬂanking regions of
COL13A1. Analysis of splicing variants was performed with
Human Splice Finder 3.1 (Desmet et al., 2009). Ethics ap-
proval for analysis of DNA and tissue samples was obtained
(OXREC B: 04.OXB.017 and Oxfordshire REC C 09/h0606/
74).
Endplate studies
Fresh frozen muscle sections from Patient 1 were labelled with
Alexa Fluor 594 conjugated -bungarotoxin (Life
Technologies, Cat. No. B13423) and Alexa Fluor 488-fasci-
culin (Life Technologies, special order) at 1 mg/ml for 1 h at
37C to stain for AChRs and acetylcholinesterase (AChE), re-
spectively. The presynaptic Schwann cell marker S100b was
labelled using a mouse monoclonal anti-S100b antibody
(Sigma, Cat. No. SAB1402349) and the corresponding ﬂuor-
escently conjugated secondary antibody (Life Technologies,
Cat. No. R37115). Then, sections were washed in PBS and
ﬁxed for 10min in 3% paraformaldehyde at room tempera-
ture. Images from the muscle endplates were taken using a
Zeiss LSM 510 inverted confocal microscope. Co-localization
studies were performed using ImageJ software (Schindelin
et al., 2012).
Data availability
The data that support the ﬁndings of this study are available
from the corresponding author, upon reasonable request.
Results
Genetic analysis
Whole exome sequencing identiﬁed 13 COL13A1 variants
in 16 subjects from 11 different kinships identiﬁed by
whole exome sequencing (Fig. 1A, B and Table 1). PCR
ampliﬁcation on genomic DNA and Sanger sequencing con-
ﬁrmed the mutations and segregation of COL13A1 vari-
ants with disease. Ten variants were loss-of-function
[nonsense (4), frameshift (3), and splice-site (3)] mutations
and three were missense. Two siblings were homozygous
for the c.523-1delG splice-site variant, which is predicted
to allow splicing but lead to premature termination
due to a single-base deletion in the coding sequence
(p.Gly175Vfs*20) (Logan et al., 2015). Two siblings were
heterozygous for the c.782-1G4A splice-site variant, which
is predicted to abolish the wild-type donor site and may
lead to activation of an intronic cryptic acceptor site. In
addition, two siblings were homozygous for the
c.549+5G4A splice site variant, which is predicted to
alter the wild-type donor site. Both splice variants were
predicted to ‘most probably’ affect splicing by Human
Splice Finder 3.1 software (Desmet et al., 2009). The
three missense variants identiﬁed (p.G509D, p.G643R and
p.P710L) were located in the C-terminal domain of the
protein and affect amino acids evolutionarily conserved
across species (Fig. 1C). In silico analysis classiﬁed all mis-
sense variants as damaging by MutationTaster (Schwarz
et al., 2010), PolyPhen-2 (Adzhubei et al., 2010) and the
SIFT algorithm (Sim et al., 2012) (Supplementary Table 1).
None of the variants identiﬁed by whole exome sequencing
were listed in Ensembl genome browser 94 [(EMBL-EBI,
Cambridge, UK (URL: https://www.ensembl.org) (Dec
2018)] (Zerbino et al., 2018) or in the 125 748 exome
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sequences and 15 708 whole-genome sequences from
unrelated subjects of the Genome Aggregation Database
[(gnomAD, Cambridge, MA (URL: http://gnomad.broadin-
stitute.org) (Dec 2018)] (Lek et al., 2016) except for
c.621delA;p.G208EfsX15 (Ensembl: allele frequency
not provided), c.271C4T;p.R91X (Ensembl: 0.001 in
ALSPAC cohort and 0.000 in TWINSUK cohort) and
c.486delT;p.G163VfsX32 (0.000004035; gnomAD),
which were classiﬁed as rare variants according to their
allele frequencies displayed in brackets.
Clinical features
Clinical presentation
Pregnancy was uneventful in all cases and normal foetal
movements were reported. Clinical presentation was
mostly at birth or shortly afterwards (median age at
onset was 0 years, range 0–1 years) with varying degrees
of feeding and breathing difﬁculties. Common features
were, ﬁrst, a number of cases (Patients 2, 5–8 and 12–13)
presented with poor suck and weight loss in the neonatal
period, and some associated additional recurrent episodes
of respiratory dysfunction. This subgroup did not require
overall prolonged artiﬁcial feeding or ventilation, although
we note that Patient 5 was not started on solid food until
the age of 3. Second, a more severe group of patients had
marked breathing and feeding difﬁculties requiring long-
term ventilation or tracheostomy and artiﬁcial feeding
from birth (Patients 1, 3, 9–11, 15 and 16). For instance,
Patient 1 had severe bulbar weakness and recurrent ap-
noeas related to diaphragmatic weakness requiring non-in-
vasive ventilation and long-term gastrostomy. In the same
way, Patient 9 was apnoeic from birth and had signiﬁcant
bulbar weakness with fatigue on crying and subsequent
evidence of failed extubations due to diaphragmatic weak-
ness and respiratory failure. Finally, on the less severe side
of the clinical spectrum, Patient 14 was only noted to have
mild hypotonia and bilateral ptosis in the ﬁrst weeks of life,
and Patient 4 presented with difﬁculties to crawl at the age
of 1 year, associated with marked neck muscle weakness
requiring a neck brace from the ages of 2 to 3 years.
Overall, bilateral ptosis (8/16) and generalized hypotonia
(10/16) from birth were reported in approximately half of
the subjects.
Pattern of muscle weakness
The predominant pattern of muscle weakness included bi-
lateral ptosis with differing degrees of severity, myopathic
facies and marked axial weakness, especially in neck ﬂexors
and trunk muscles (Fig. 2A and B). Limb muscles were
generally less severely affected. Interestingly, in adult
cases, ptosis was mainly described as non-ﬂuctuating and
was usually non-fatigable on examination. Eye movements
were fully preserved except for mild restriction of upgaze in
a few (Patients 3, 4, 6 and 13) and no double vision was
reported. The presence of a squint was only noted in
Patient 6. All cases had myopathic facies with mild to mod-
erate facial weakness involving eye closure and muscles of
the lower face. There was marked weakness in neck ﬂexors
and extensors and truncal muscles, with a number of pa-
tients experiencing poor head control (Fig. 2C) and scoli-
osis (Fig. 2D). Weakness in proximal limbs was generally
present early in life but improved gradually over time, with
some patients having no detectable weakness in adulthood
(Patients 2, 4, 12 and 13). Mild distal weakness in upper
and lower limbs was noted in half of the cases.
Respiratory function
Respiratory function was compromised in the majority of
patients, though with differing degrees of severity, including
four patients requiring long-term tracheostomy soon after
birth. Episodes of respiratory deterioration were frequent
early in life, and ventilator support was often needed.
Respiratory crisis were either triggered by chest infections
or occurred spontaneously, and some patients had asso-
ciated bibasilar atelectasis probably related to diaphrag-
matic weakness. Overall, the prognosis over time was
favourable with a reduction in the frequency of respiratory
events, although they still occurred in some adult cases with
reduced vital capacity and chest abnormalities: Patient 4
had two respiratory crises triggered by chest infections at
the age of 32 years following a long period of stability of
more than a decade. Patients 12 and 13 suffered from daily
somnolence in adulthood and were diagnosed with ob-
structive sleep apnoea by polysomnography and subse-
quently started on nocturnal non-invasive ventilation.
Additional clinical features
Dysmorphic features were noted in all cases except Patients
7, 8 and 10. These included elongated face, low-set ears,
micrognathia and high-arched palate (Fig. 2). In addition,
some patients (Patients 1–3, 5, 6 and 15) had prominent
skeletal abnormalities, especially of the chest (Fig. 2A and D),
with the presence of pectus carinatum from early life.
Patients 4, 5, 12, 13 and 16 developed moderate to
severe scoliosis with associated thoracic kyphosis and re-
stricted lung capacity in some cases (Fig. 2D). Spinal fusion
surgery was performed in Patients 4 and 16 at the age of 8
and 13 years, respectively. Mild spinal rigidity was present
in Patients 2 and 3 but no distal or proximal contractures
were noted in any patient. Joint laxity was not a striking
feature and was only noted mild distally in Patients 1, 3
and 11–13. An overall thin appearance with generalized
reduced muscle bulk was reported in the records of
Patients 2, 4, 5, 12 and 13.
Mild learning difﬁculties were present in Patients 1, 2, 5,
6 and 10, while Patient 11 had severe cognitive delay with
autism spectrum disorder and self-injurious behaviour. At
the age of 8 years, he is able to follow simple commands
and has 30–40 words in his vocabulary. Patient 15 had
moderate cognitive delay and self-mutilation behaviour sec-
ondary to congenital insensitivity to pain with anhidrosis
due to a homozygous mutation in NTRK1 (Mardy et al.,
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1999). Skin abnormalities were only noted in Patient 1 with
mild keratosis pilaris. There were no signs suggestive of
skin hyperextensibility or hypertrophic scarfs. Patient 3
had a combined hiatus and diaphragmatic hernia that wor-
sened her respiratory function. Patient 5 had delayed recov-
ery from general anaesthesia at age 2 months following
surgery for a unilateral inguinal hernia.
Response to treatment
While there was no clear response to cholinesterase inhibi-
tors, treatment with 3,4-diaminopyridine (3,4-DAP, 0.3–
0.9mg/kg/day) and salbutamol (0.05–0.56mg/kg/day) re-
sulted in improved motor and respiratory function.
Treatment with 3,4-DAP (0.3mg/kg/day) and salbutamol
(0.56mg/kg/day) was effective in Patient 1, leading to
better head control, improved unassisted sitting and
reduced requirement for non-invasive ventilation. Previous
treatment with pyridostigmine (up to 6mg/kg/day) was
only transiently beneﬁcial. Patient 2 did not respond to
treatment with pyridostigmine up to 6mg/kg/day in
childhood. Further treatment was not attempted because
of the normalization of his muscle strength in adulthood.
Patient 3 was not initiated on pyridostigmine because of
parental choice at the time of clinical diagnosis. Patient 4
had no further respiratory crisis to date on treatment with
salbutamol (0.17mg/kg/day) although neck weakness con-
tinues to be marked. Patient 5 was already on treatment
with salbutamol inhaler for asthma and therefore further
treatment was not advised. Patient 6 improved his axial
strength and fatigue levels on treatment with 3,4-DAP
(0.9mg/kg/day) and salbutamol (0.2mg/kg/day). Patient 7
was treated with pyridostigmine and salbutamol inhaler
(because of asthma) with apparent improvement in her
ptosis. Patient 8 did not receive pharmacological treatment
for her mild myasthenic symptoms. Treatment with salbu-
tamol (up to 0.2mg/kg/day) in Patient 9 was initially useful
to wean from invasive to non-invasive ventilation.
Subsequent introduction of 3,4-DAP (0.3mg/kg/day)
helped to improve his head control and limb strength and
reduce his fatigue when crying. Patient 10 was started on
Figure 2 Clinical features of patients with COL13A1mutations. (A and B) Presence of bilateral ptosis and dysmorphic features including
elongated face, micrognathia and low-set ears (Patients 12 and 13). (C) Marked weakness in neck flexors and truncal muscles with poor head
control (Patient 1). (D) Severe scoliosis and associated thoracic kyphosis with restricted lung capacity (Patient 5).
The clinical spectrum of COL13A1-CMS BRAIN 2019: 142; 1547–1560 | 1553
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/6/1547/5488581 by St G
eorge's U
niversity of London user on 02 O
ctober 2019
3,4-DAP (0.3mg/kg/day) and albuterol (0.56mg/kg/day) at
3 months of age with overall improvement in motor func-
tion and gain of antigravity power in limbs and ability to
sit without support. The response to treatment in Patient
11 has not been assessed. Patients 12–14 did not respond
to treatment with pyridostigmine. Patient 16 had some im-
provement on 3,4-DAP, which was helpful for decannula-
tion and switching to non-invasive ventilation and removal
of gastrostomy at age 4 years. Subsequent addition of sal-
butamol (0.15mg/kg/day) resulted in clear respiratory im-
provement (vital capacity increased from 20% to 40% of
the predicted value) with no respiratory crisis in the last
5 years.
Course of disease
Most patients improved over time with regards to their
motor and respiratory function, including a decrease in
the frequency of respiratory events (Fig. 3). This was obvi-
ous in the adults (Patients 2, 4, 5, 12, 13 and 16) where
examination showed absent or minimal weakness in limb
muscles despite some of them not being on treatment at the
time of diagnosis. By contrast, axial weakness persisted in
adulthood with most cases experiencing ongoing moderate
to severe neck weakness and poor head control.
Respiratory function was also impaired in adult patients
with reduced vital capacity, scoliosis and morphological
abnormalities of the chest (Patients 4, 5, 12 and 13). All
adult patients were fully ambulant although Patient 5 could
walk only up to 400m before he became fatigued and short
of breath. The milder paediatric cases (Patients 6–8 and 14)
gradually improved with age although remain affected with
bilateral ptosis and mild to moderate axial weakness, but
free of respiratory events. The more severe paediatric cases
with onset of symptoms at birth (Patients 1, 9 and 10)
continue to make good progress except for Patient 11
who gained the ability to cruise at age 5 years but subse-
quently lost it and since then has been wheelchair-depend-
ent. Patient 1 at 5 years of age is currently able to walk
independently around the house but uses a wheelchair for
longer distances. She is largely percutaneous endoscopic
gastrostomy (PEG)-fed and uses non-invasive ventilation
at night, although she has remained free of respiratory
crisis since salbutamol was initiated at 2 years of age.
Axial weakness is still present with sub-gravity neck ﬂexion
strength and poor head control. Patient 9 remains PEG-fed
and ventilated via tracheostomy at age 2 years. However,
there has been a reduction in fatigue and progress in his
abilities with less frequent need for suctioning, acquisition
of the ability to sit and improvement in head control and
limbs strength. Patient 10 continues to have poor head
control with inability to stand without support at age 23
months. He requires nocturnal non-invasive ventilation and
is fully PEG-fed. Patient 3 died at the age of 8 years from
chronic respiratory failure attributed to muscle weakness
and diaphragmatic hernia, and Patient 15 died at the age
of 20 years from a choking episode.
Investigations
Muscle biopsy
Nine patients underwent muscle biopsy (age range: 6
months–17 years), which was described as normal or
showed mild non-speciﬁc changes (Table 2 and Fig. 4).
These included: mild variation in ﬁbre size (Patients 1, 5,
6 and 12; Fig. 4A and G) and the presence of a few internal
nuclei (Patient 1); mild increase in connective tissue
(Patients 12 and 15); mild type 1 ﬁbre predominance
(Patient 5; Fig. 4C); and mild changes in oxidative staining
with some ﬁbres giving a moth-eaten (Patient 12; Fig. 4I) or
a halo-like appearance (Patient 1). Occasional peripheral
vacant vacuole-like areas with haematoxylin and eosin
stain and several hypercontracted ﬁbres with Go¨mo¨ri tri-
chrome stain were seen in Patient 1 although an artefactual
effect cannot be ruled out (Logan et al., 2015).
Neurophysiology
All patients tested had results consistent with abnormal
neuromuscular transmission (Table 2). Repetitive nerve
stimulation at 3Hz showed the presence of signiﬁcant dec-
rement in 9 of 13 patients in proximal and/or distal mus-
cles of the upper limbs. Frequency dependent decrement
was not routinely assessed. No repetitive discharges or in-
crement to volitional contraction was observed. Single ﬁbre
electromyography (SFEMG) showed increased jitter or
blocking in all nine patients tested. Nerve conduction stu-
dies were normal whenever performed. Needle EMG exam-
ination showed additional myopathic features in Patients 5,
6 and 15.
Other investigations
Serum creatine kinase levels were normal in all cases.
Patient 10 initially had raised creatine kinase levels in the
neonatal period at 900 IU/l but values subsequently normal-
ized to 47 IU/l. Brain MRI and muscle MRI of the lower
limbs were reported as normal in all cases performed
(Fig. 4D–F and J–L). Whole body muscle MRI, conducted
in Patients 13 and 16 at the age of 21 and 15 years,
respectively, showed changes suggestive of atrophy and
moderate fatty replacement in the paraspinal muscles,
although we note Patient 16 had spinal fusion surgery at
age 13.
Endplate studies
Co-localization studies in muscle endplates showed positive
expression of AChRs and AChE but lack of complete over-
lap between the two ﬂuorescent dyes with the contour of
the acetylcholinesterase staining (green) exceeding the limits
of the -bungarotoxin staining (red) (Fig. 5A). Staining for
the presynaptic marker S100b labelled terminal Schwann
cells reaching the muscle endplates (Fig. 5B).
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Discussion
We describe the clinical spectrum of disease associated with
COL13A1 mutations and report a series of novel patho-
genic mutations in this recently described CMS causative
gene. Patients with COL13A1 mutations underlie a
myasthenic syndrome characterized by early onset muscle
weakness with predominantly feeding and breathing difﬁ-
culties often requiring ventilation and artiﬁcial feeding. The
pattern of muscle weakness is predominantly axial with
marked bulbar, neck and truncal weakness rather than ap-
pendicular. Scoliosis can be severe and therefore careful
monitoring of the spinal curvature is recommended.
Patients improve on treatment with 3,4-DAP and salbuta-
mol with regards to their motor and respiratory function,
whereas pyridostigmine was not beneﬁcial. Disease severity
improves gradually over time with reduced frequency of
respiratory events with age and some patients having no
or only mild muscle weakness on examination in
adulthood.
Collagens are important components of the synaptic
basal lamina, a specialized form of extracellular matrix
that lies in the intersynaptic space and is essential for the
neuromuscular junction architecture and function (Patton,
2003). Additional elements include laminins, heparan sul-
phate proteoglycans (muscle agrin and perlecan) and nido-
gens (Shi et al., 2012). For many years, mutations in
COLQ encoding the collagen-like tail subunit of asymmet-
ric AChE were the only identiﬁed subtype of synaptic basal
lamina-associated CMS (Ohno et al., 1998). This has been
expanded with the report of CMS due to LAMB2 (Maselli
et al., 2009), LAMA5 (Maselli et al., 2017) and COL13A1
mutations (Logan et al., 2015), which has helped to in-
crease our understanding on the contribution of the
synaptic basal lamina to the organization of the neuromus-
cular synapse.
COL13A1-disease shares with other myasthenic syn-
dromes the presence of fatigable muscle weakness and ab-
normal neurophysiology with decremental response to
repetitive nerve stimulation and/or abnormal jitter on
SFEMG. More speciﬁc features include facial dysmorphism,
skeletal abnormalities of the chest, and a lack of beneﬁcial
response to cholinesterase inhibitors (Supplementary Table
2). Of interest, we note that similar facial and skeletal fea-
tures have been reported in patients with King-Denborough
syndrome (King and Denborough, 1973) although these are
overall non-speciﬁc features and therefore can be found in
other syndromes. King-Denborough syndrome is a rare
condition characterized by dysmorphic features including
ptosis, skeletal abnormalities, myopathy and malignant
hyperthermia susceptibility, although the latter is not
always present (Dowling et al., 2011). The cause of King-
Denborough syndrome is not fully understood, although
some cases have been attributed to mutations in RYR1
(D’Archy et al., 2008).
Unlike other CMS, ptosis in patients with COL13A1-
CMS is non-ﬂuctuating and non-fatigable on examination
in adulthood, compared to an early age. We could specu-
late that this might indicate a concomitant myopathic pro-
cess impairing the levator palpebrae superioris function.
We note that needle EMG examination showed myopathic
changes in several patients, although creatine kinase levels,
muscle biopsy and muscle MRI studies were overall
normal, which is consistent with a myasthenic syndrome
considering the degree of muscle weakness seen in the pa-
tients. Endplate studies carried out in the muscle biopsy of
Patient 1 showed the incomplete overlap between acetyl-
choline receptors and acetylcholinesterase staining. The
Figure 3 Course of disease in patients with COL13A1-CMS. The proposed course of disease in COL13A1-CMS based on the obser-
vations made from the cases reported in this study. Axial weakness remained severe throughout the disease course while limb weakness and
bulbar weakness improved over time. The respiratory function also improved with time but some adult patients had respiratory crisis or needed
non-invasive ventilation most likely due to morphological abnormalities of the chest and the spine causing reduced vital capacity.
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signiﬁcance of this ﬁnding is unclear but we note that this
has also been reported in the Col13a1/ animal model
(Ha¨ro¨nen et al., 2017).
In general, CMS type 19 lies on the severe side of the
CMS spectrum, with a meaningful proportion of patients
having life-threatening feeding and breathing difﬁculties
early in life. However, a small number of patients fall on
the mild side of the spectrum (Patients 7 and 14) with
minimal weakness and lack of respiratory events, which
reﬂects a broad clinical spectrum. Phenotype-genotype cor-
relation suggests that patients with missense mutations may
have milder symptoms compared to those harbouring loss-
of-function mutations. In keeping with this, none of the
four patients reported with missense mutations required
tracheostomy or artiﬁcial feeding, although Patient 5 has
severe chest abnormalities and reduced vital capacity in
adulthood.
The nature of the respiratory issues early in life is not
clear, and it seems not to be correlated with limb weak-
ness. The observation that some patients developed biba-
silar atelectasis during the respiratory episodes points to
diaphragmatic weakness, although weakness of accessory
respiratory muscles and stiffness of the rib cage could also
play a role. Other factors that seem to inﬂuence patients’
respiratory outcome in adulthood are the spine and chest
abnormalities that may lead to restrictive lung disease and
low vital capacity. Therefore, spinal curvature should be
monitored periodically from early childhood.
Table 2 Clinical investigations of patients with CMS type 19
Family 1 Family 2 Family 3 Family 4 Family 5 Family 6
Affected individual Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Vital capacity, l, (% predicted) – 2.88 (62) – 1.08 (29) 0.75 (23) – – –
Abnormal RNS decrement (410%) Y Y – Y N N Y Y
Muscle ADM, FHB Anconeous – Trapezius FCU NA ADM, FHB ADM, FHB
Abnormal SFEMG Y Y – Y Y Y – –
Muscle OO EDC – OO OO OO – –
MCD, ms 133.3 69.8 – 173.8 68.7 75.0 – –
Increased jitter Y Y – Y Y NA – –
Blocking Y N – N Y NA – –
Muscle biopsy (age) Y (6 m) – Y (1 y) Y (3 y) Y (5 y) Y (1 y) – –
Muscle Quadriceps – Quadriceps NA Quadriceps Quadriceps – –
Result Non-specific – Normal NA Non-specific Non-specific – –
Muscle MRI Normal – – – Normal – – –
CK (IU/l) 35 – – 212 141 Normala Normala Normala
Brain MRI – – – – Normal – – –
Family 7 Family 8 Family 9 Family 10 Family 11
Affected individual Patient 9 Patient 10 Patient 11 Patient 12 Patient 13 Patient 14 Patient 15 Patient 16
Vital capacity, l,
(% predicted)
– – – 1.43 (29%) b – 0.65 (14%)c 0.55 (23%)
Abnormal RNS
decrement (410%)
– – Y N N Y Y Y
Muscle – – Na ADM, deltoid,
TA, nasalis
ADM, deltoid,
TA, nasalis
EDC, deltoid, ADM ADM
Abnormal SFEMG – – – Y Y – Y Y
Muscle – – – OO OO – EDC EDC
MCD (ms) – – – 73 76 – 96 50
Increased jitter – – – Y Y – Y Y
Blocking – – – NA NA – NA Y
Muscle biopsy (age) – – Y (8 m) Y (17 y) – – Y (6 m) Y (15 y)
Muscle – – Deltoid Biceps brachialis – – Quadriceps Quadriceps
Result – – Non-specific Non-specific – – Non-specific Non-specific
Muscle MRI – – – Normal Paraspinal,
atrophy
– – Paraspinal,
atrophy
CK (IU/l) Normal 900 ! 47 81 63 45 68 100 41
Brain MRI Normal Normal Normal – – – Normal Normal
ADM = abductor minimi digiti; CK = creatine kinase; FCU = flexor carpi ulnaris; FHB = flexor hallucis brevis; m = months; N = no; NA = not available; OO = orbicularis oculi;
QMG = quantitative myasthenia gravis score; RNS = repetitive nerve stimulation; SFEMG = single-fibre EMG; WES = whole exome sequencing; y = years; Y = yes.
aSpecific values are not available but recorded as normal in the patients’ records.
bSpecific value not available but reported as ‘similar to sibling’ in the patient’s records.
cPatient was not fully collaborative during the test.
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Evaluation in adulthood suggests that patients with CMS
type 19 improve gradually over time with regard to their
respiratory and motor function, although some adult patients
can also present with ongoing respiratory problems if their
vital capacity is compromised. Recent experimental studies in
Col13a1/ animals have shown that disease severity stabil-
izes in adult mice once the neuromuscular junctions have
matured (Zainul et al., 2018). These ﬁndings suggest that
this subtype of CMS could be particularly severe early in
life due to the more prominent role of COL13A1 in the
formation and maturation of the muscle endplate. We have
not observed long-term ﬂuctuations as reported in patients
with DOK7 mutations (Muller et al., 2007).
Patients with COL13A1 mutations do not appear to re-
spond to treatment with pyridostigmine, but 3,4-DAP and
salbutamol have been beneﬁcial in improving motor and
respiratory function. 3,4-DAP acts by blocking potassium
channels at the presynaptic terminal and expands the dur-
ation of acetylcholine release, which would help compen-
sate for the presynaptic abnormalities derived from the
Figure 4 Clinical investigations of patients with COL13A1mutations. Muscle biopsy from the quadriceps muscle in Patient 5 at the age
of 5 years showed mild changes on haematoxylin and eosin stain (A) and modified Gomori trichrome (B), and type 1 fibre predominance on the
ATPase 4.3 enzyme histochemical stain (C). Muscle MRI of his pelvis and lower limbs at the age of 13 years was normal (D–F). Muscle biopsy from
the biceps brachialis in Patient 12 at the age of 17 years showed mild variability of fibre size on haematoxylin and eosin stain (G). Modified Gomori
trichrome staining showed a mild increase in perimysial connective tissue (H) and nicotinamide adenine dinucleotide tetrazolium reductase
(NADH-TR) stain showed mild disruption of the myofibrillar architecture (I). Muscle MRI of his pelvis and lower limbs showed no abnormalities
(J–L).
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COL13A1 loss. The molecular mechanism of salbutamol at
the neuromuscular junction is still not fully understood but
recent insight supports an effect on maintenance of synaptic
integrity (Clausen et al., 2018; Mcmacken et al., 2018).
This suggests that b2-adrenergic agonists could work by
compensating for the postsynaptic abnormalities and lack
of endplate maturation derived from the loss of COL13A1
function. Early introduction of b2-adrenergic agonists
could prove helpful to stabilize respiratory function and
reduce the number of respiratory events, as observed in
some of the cases reported here. The lack of response to
pyridostigmine and the robust alpha-bungarotoxin endplate
staining argue against a deﬁciency of endplate AChR.
RNA expression studies have shown that COL13A1 is
widely expressed in different tissues. Therefore, it is unclear
why COL13A1 mutations primarily affect the neuromus-
cular junction although immunostaining does shows that
COL13A1 is highly concentrated at the neuromuscular
junction. A similar phenomenon occurs in patients with
CMS and mutations within the N-glycosylation pathway,
which is ubiquitously expressed (Belaya et al., 2012;
Cossins et al., 2013; Zoltowska et al., 2013). In connexion
with this, several patients with COL13A1 mutations had
mild learning difﬁculties and one suffered from severe
mental retardation within the autistic spectrum. It is pos-
sible that the cognitive impairment could be attributed to
the loss of COL13A1 expressed in the brain (Uhle´n et al.,
2015). However, additional contributing factors may
include consanguinity, which is a well-known risk factor
for genetic disorders that present with intellectual disability,
and respiratory crisis early in life. The latter could result in
hypoxic changes in the CNS, although brain MRI did not
identify any structural abnormalities in the cases available.
Finally, although less likely, cognitive deﬁcits are relatively
common in the general population, and their co-occurrence
with COL13A1-CMS might be incidental. Future studies
using standardized neuropsychological tests will be helpful
to understand whether there is a speciﬁc defective pattern
in cognition
In conclusion, this study expands the clinical and genetic
spectrum of COL13A1 disease and highlights the import-
ance of collagens at the neuromuscular junction. The de-
tailed description of clinical and complementary features of
patients with CMS type 19 should facilitate the recognition
and appropriate treatment of patients with this condition.
This work also highlights the increasingly important role of
next generation sequencing in routine clinical practice for
reaching a deﬁnite genetic diagnosis.
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